Drugs like Ozempic, which have become increasingly popular for losing weight, heighten the risk of certain severe gastrointestinal problems including stomach paralysis, according to a large study published Thursday.
The paper, published in the Journal of the American Medical Association (JAMA), looked at a class of drugs called GLP-1 agonists that includes the brands Wegovy, Ozempic, Rybelsus and Saxenda.
It then compared the rate of serious side effects to another class of weight loss drug, bupropion-naltrexone.